{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T20:16:21Z","timestamp":1770840981345,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"The 16th batch of \u201cSix Talent Peak\u201d projects in Jiangsu Province of China","award":["WSN-035"],"award-info":[{"award-number":["WSN-035"]}]},{"name":"The 16th batch of \u201cSix Talent Peak\u201d projects in Jiangsu Province of China","award":["WSN-035"],"award-info":[{"award-number":["WSN-035"]}]},{"name":"The 16th batch of \u201cSix Talent Peak\u201d projects in Jiangsu Province of China","award":["WSN-035"],"award-info":[{"award-number":["WSN-035"]}]},{"name":"The 16th batch of \u201cSix Talent Peak\u201d projects in Jiangsu Province of China","award":["WSN-035"],"award-info":[{"award-number":["WSN-035"]}]},{"name":"The 16th batch of \u201cSix Talent Peak\u201d projects in Jiangsu Province of China","award":["WSN-035"],"award-info":[{"award-number":["WSN-035"]}]},{"name":"The 16th batch of \u201cSix Talent Peak\u201d projects in Jiangsu Province of China","award":["WSN-035"],"award-info":[{"award-number":["WSN-035"]}]},{"name":"The 16th batch of \u201cSix Talent Peak\u201d projects in Jiangsu Province of China","award":["WSN-035"],"award-info":[{"award-number":["WSN-035"]}]},{"name":"The 16th batch of \u201cSix Talent Peak\u201d projects in Jiangsu Province of China","award":["WSN-035"],"award-info":[{"award-number":["WSN-035"]}]},{"name":"The 16th batch of \u201cSix Talent Peak\u201d projects in Jiangsu Province of China","award":["WSN-035"],"award-info":[{"award-number":["WSN-035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Studies reporting the effects of metabolic surgery, lifestyle intervention, and intensive insulin therapy for the remission of type 2 diabetes (T2DM) has been increasing, with fruitful results better conducted and yielded. However, there are only a few studies on the remission of T2DM using oral hypoglycemic drugs. Therefore, this study aims to investigate the remission effect of canagliflozin and metformin on participants with newly diagnosed T2DM and its possible underlying mechanism(s) through which these two medications elicit diabetes remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Method<\/jats:title>\n                <jats:p>To this end, we performed a multicenter, parallel-group, randomized, controlled, and open-label trial. A total of 184 participants with a\u2009\u2264\u20093-year course of T2DM will be enrolled and randomly assigned to the canagliflozin or metformin treatment group in a ratio of 1:1. Participants in each group will maintain their medication for 3 months after achieving the target blood glucose level and then stop it. These participants will be followed up for one year to determine remission rates in both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>In this study, we will establish that whether canagliflozin is superior to metformin in terms of remission rate in participants with newly diagnosed T2DM. The results of this trial may provide robust evidence regarding the efficacy and mechanisms of the action of sodium-glucose cotransporter-2 inhibitors (SGLT2is) in T2DM remission.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ChiCTR2100043770(February 28, 2021).<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-023-01461-9","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T03:25:06Z","timestamp":1696908306000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Remission effect of Canagliflozin in patients with newly diagnosed type 2 diabetes mellitus: a protocol for a multicenter, parallel-group, randomized, controlled, open-label trial"],"prefix":"10.1186","volume":"23","author":[{"given":"Xue","family":"Yang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiwei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenbin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doudou","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pingping","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guofang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"1461_CR1","doi-asserted-by":"publisher","first-page":"417","DOI":"10.2147\/VHRM.S345810","volume":"18","author":"L Shibib","year":"2022","unstructured":"Shibib L, Al-Qaisi M, Ahmed A, Miras AD, Nott D, Pelling M, et al. Reversal and remission of T2DM - an update for practitioners. Vasc Health Risk Manag. 2022;18:417\u201343. https:\/\/doi.org\/10.2147\/VHRM.S345810.","journal-title":"Vasc Health Risk Manag"},{"key":"1461_CR2","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/S2213-8587(19)30068-3","volume":"7","author":"MEJ Lean","year":"2019","unstructured":"Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7:344\u201355. https:\/\/doi.org\/10.1016\/S2213-8587(19)30068-3.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1461_CR3","doi-asserted-by":"publisher","first-page":"123","DOI":"10.7570\/jomes22001","volume":"31","author":"JH Ko","year":"2022","unstructured":"Ko JH, Kim TN. Type 2 diabetes remission with significant weight loss: definition and evidence-based interventions. J Obes Metab Syndr. 2022;31:123\u201333. https:\/\/doi.org\/10.7570\/jomes22001.","journal-title":"J Obes Metab Syndr"},{"key":"1461_CR4","first-page":"593","volume":"105","author":"ES Banerjee","year":"2022","unstructured":"Banerjee ES, Schroeder R, Harrison TD. Metabolic surgery for adult obesity: common questions and answers. Am Fam Phys. 2022;105:593\u2013601. PMID: 35704821.","journal-title":"Am Fam Phys"},{"key":"1461_CR5","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1177\/1559827620930962","volume":"14","author":"J Kelly","year":"2020","unstructured":"Kelly J, Karlsen M, Steinke G. Type 2 diabetes remission and lifestyle medicine: a position statement from the american college of lifestyle medicine. Am J Lifestyle Med. 2020;14:406\u201319. https:\/\/doi.org\/10.1177\/1559827620930962.","journal-title":"Am J Lifestyle Med"},{"key":"1461_CR6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.4093\/dmj","volume":"46","author":"J Kim","year":"2022","unstructured":"Kim J, Kwon HS. Not control but conquest: strategies for the remission of type 2 diabetes mellitus. Diabetes Metab J. 2022;46:165\u201380. https:\/\/doi.org\/10.4093\/dmj.","journal-title":"Diabetes Metab J"},{"key":"1461_CR7","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.2337\/diacare.27.11.2597","volume":"27","author":"Y Li","year":"2004","unstructured":"Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, et al. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function. Diabetes Care. 2004;27:2597\u2013602. https:\/\/doi.org\/10.2337\/diacare.27.11.2597.","journal-title":"Diabetes Care"},{"key":"1461_CR8","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/jdi.12813","volume":"9","author":"H Hirukawa","year":"2018","unstructured":"Hirukawa H, Hashiramoto M, Tanizawa Y, Kaku K. Pioglitazone and Sulfonylurea Remission from Type 2 diabetes Mellitus and Anti-Atherosclerosis in Japan (PREVENT-J) study group. Remission of hyperglycemia after withdrawal of oral antidiabetic drugs in japanese patients with early-stage type 2 diabetes. J Diabetes Investig. 2018;9:1119\u201327. https:\/\/doi.org\/10.1111\/jdi.12813.","journal-title":"J Diabetes Investig"},{"key":"1461_CR9","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1089\/dia.2008.0045","volume":"10","author":"ST Chandra","year":"2008","unstructured":"Chandra ST, Priya G, Khurana ML, Jyotsna VP, Sreenivas V, Dwivedi S, et al. Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes. Diabetes Technol Ther. 2008;10:363\u20138. https:\/\/doi.org\/10.1089\/dia.2008.0045.","journal-title":"Diabetes Technol Ther"},{"key":"1461_CR10","first-page":"333","volume":"55","author":"V Panikar","year":"2007","unstructured":"Panikar V, Joshi SR, Bukkawar A, Nasikkar N, Santwana C. Induction of long-term glycemic control in type 2 diabetic patients using pioglitazone and metformin combination. J Assoc Physicians India. 2007;55:333\u20137. PMID: 17844692.","journal-title":"J Assoc Physicians India"},{"key":"1461_CR11","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.2337\/dc21-2136","volume":"45","author":"N Holman","year":"2022","unstructured":"Holman N, Wild SH, Khunti K, Knighton P, O\u2019Keefe JH, Bakhai C, et al. Incidence and characteristics of remission of type 2 diabetes in England: a cohort study using the national diabetes audit. Diabetes Care. 2022;45:1151\u201361. https:\/\/doi.org\/10.2337\/dc21-2136.","journal-title":"Diabetes Care"},{"key":"1461_CR12","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3390\/jcm7090235","volume":"7","author":"M Seghieri","year":"2018","unstructured":"Seghieri M, Rebelos E, Mari A, Sciangula L, Giorda C, Ferrannini E. Short course of insulin treatment versus metformin in newly diagnosed patients with type 2 diabetes. J Clin Med. 2018;7:235. https:\/\/doi.org\/10.3390\/jcm7090235.","journal-title":"J Clin Med"},{"key":"1461_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1016\/S2213-8587(19)30076-2","volume":"7","author":"R Taylor","year":"2019","unstructured":"Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7:726\u201336. https:\/\/doi.org\/10.1016\/S2213-8587(19)30076-2.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1461_CR14","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1146\/annurev-med-042017-094221","volume":"70","author":"CK Kramer","year":"2019","unstructured":"Kramer CK, Zinman B. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors and the treatment of type 2 diabetes. Annu Rev Med. 2019;70:323\u201334. https:\/\/doi.org\/10.1146\/annurev-med-042017-094221.","journal-title":"Annu Rev Med"},{"key":"1461_CR15","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1111\/dom.14437","volume":"23","author":"I Idris","year":"2021","unstructured":"Idris I, Zhang R, Mamza JB, Ford M, Morris T, Banerjee A, et al. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: a retrospective cohort study in UK primary care. Diabetes Obes Metab. 2021;23:2207\u201314. https:\/\/doi.org\/10.1111\/dom.14437.","journal-title":"Diabetes Obes Metab"},{"key":"1461_CR16","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/1753-0407.12494","volume":"9","author":"H Kaneto","year":"2017","unstructured":"Kaneto H, Obata A, Kimura T, Shimoda M, Okauchi S, Shimo N, et al. Beneficial effects of sodium-glucose cotransporter 2 inhibitors for preservation of pancreatic \u03b2-cell function and reduction of insulin resistance. J Diabetes. 2017;9:219\u201325. https:\/\/doi.org\/10.1111\/1753-0407.12494.","journal-title":"J Diabetes"},{"key":"1461_CR17","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/j.soard.2020.05.013","volume":"16","author":"I Elgenaied","year":"2020","unstructured":"Elgenaied I, El Ansari W, Elsherif MA, Abdulrazzaq S, Qabbani AS, Elhag W. Factors associated with complete and partial remission, improvement, or unchanged diabetes status of obese adults 1 year after sleeve gastrectomy. Surg Obes Relat Dis. 2020;16:1521\u201330. https:\/\/doi.org\/10.1016\/j.soard.2020.05.013.","journal-title":"Surg Obes Relat Dis"},{"key":"1461_CR18","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1111\/1753-0407.12581","volume":"9","author":"J Weng","year":"2017","unstructured":"Weng J. Short-term intensive insulin therapy could be the preferred option for new onset type 2 diabetes mellitus patients with HbA1c > 9. J Diabetes. 2017;9:890\u20133. https:\/\/doi.org\/10.1111\/1753-0407.12581.","journal-title":"J Diabetes"},{"key":"1461_CR19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.3390\/nu11040766","volume":"11","author":"SJ Hallberg","year":"2019","unstructured":"Hallberg SJ, Gershuni VM, Hazbun TL, Athinarayanan SJ. Reversing type 2 diabetes: a narrative review of the evidence. Nutrients. 2019;11:766. https:\/\/doi.org\/10.3390\/nu11040766.","journal-title":"Nutrients"},{"key":"1461_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-00676-z","author":"SM Sidik","year":"2023","unstructured":"Sidik SM. Diabetes and obesity are rising globally - but some nations are hit harder. Nature. 2023. https:\/\/doi.org\/10.1038\/d41586-023-00676-z.","journal-title":"Nature"},{"key":"1461_CR21","unstructured":"IDF diabetes atlas. 10th ed. Int Diabetes Federation. 2022. (http:\/\/www.diabetesatlas.org\/)."},{"key":"1461_CR22","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12911-022-01915-5","volume":"22","author":"X Wang","year":"2022","unstructured":"Wang X, Lin Y, Xiong Y, Zhang S, He Y, He Y, et al. Using an optimized generative model to infer the progression of complications in type 2 diabetes patients. BMC Med Inform Decis Mak. 2022;22:174. https:\/\/doi.org\/10.1186\/s12911-022-01915-5.","journal-title":"BMC Med Inform Decis Mak"},{"key":"1461_CR23","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1016\/S2589-7500(22)00187-X","volume":"5","author":"V Kuan","year":"2023","unstructured":"Kuan V, Denaxas S, Patalay P, Nitsch D, Mathur R, Gonzalez-Izquierdo A, et al. Identifying and visualising multimorbidity and comorbidity patterns in patients in the english national health service: a population-based study. Lancet Digit Health. 2023;5:e16\u201327. https:\/\/doi.org\/10.1016\/S2589-7500(22)00187-X.","journal-title":"Lancet Digit Health"},{"key":"1461_CR24","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jad.2023.02.122","volume":"329","author":"A Arsh","year":"2023","unstructured":"Arsh A, Afaq S, Carswell C, Bhatti MM, Ullah I, Siddiqi N. Effectiveness of physical activity in managing co-morbid depression in adults with type 2 diabetes mellitus: a systematic review and meta-analysis. J Affect Disord. 2023;329:448\u201359. https:\/\/doi.org\/10.1016\/j.jad.2023.02.122.","journal-title":"J Affect Disord"},{"key":"1461_CR25","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.jad.2023.02.097","volume":"330","author":"J Dibato","year":"2023","unstructured":"Dibato J, Montvida O, Paul SK. Racial disparity in the co-occurrence of depression and type 2 diabetes mellitus. An electronic medical record study involving african american and white caucasian adults from the US. J Affect Disord. 2023;330:173\u20139. https:\/\/doi.org\/10.1016\/j.jad.2023.02.097.","journal-title":"J Affect Disord"},{"key":"1461_CR26","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/dme.13851","volume":"36","author":"R Taylor","year":"2019","unstructured":"Taylor R, Barnes AC. Can type 2 diabetes be reversed and how can this best be achieved? James Lind Alliance research priority number one. Diabet Med. 2019;36:308\u201315. https:\/\/doi.org\/10.1111\/dme.13851.","journal-title":"Diabet Med"},{"key":"1461_CR27","doi-asserted-by":"publisher","first-page":"2438","DOI":"10.2337\/dci21-0034","volume":"30","author":"MC Riddle","year":"2021","unstructured":"Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus report: definition and interpretation of remission in type 2 diabetes. Diabetes Care. 2021;30:2438\u201344. https:\/\/doi.org\/10.2337\/dci21-0034.","journal-title":"Diabetes Care"},{"key":"1461_CR28","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1136\/bmj.2.5154.731","volume":"2","author":"A Bloom","year":"1959","unstructured":"Bloom A. Remission in diabetes. Br Med J. 1959;2:731\u20134. https:\/\/doi.org\/10.1136\/bmj.2.5154.731.","journal-title":"Br Med J"},{"key":"1461_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/dom.14274","author":"G Thom","year":"2020","unstructured":"Thom G, McIntosh A, Taylor R, Leslie WS, Barnes AC, Brosnahan N, et al. Weight loss-induced increase in fasting ghrelin concentration is a predictor of weight regain: evidence from the diabetes Remission Clinical Trial (DiRECT). Diabetes Obes Metab. 2020. https:\/\/doi.org\/10.1111\/dom.14274.","journal-title":"Diabetes Obes Metab"},{"key":"1461_CR30","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1007\/s00464-018-6541-1","volume":"33","author":"EM Aleassa","year":"2019","unstructured":"Aleassa EM, Hassan M, Hayes K, Brethauer SA, Schauer PR, Aminian A. Effect of revisional bariatric surgery on type 2 diabetes mellitus. Surg Endosc. 2019;33:2642\u20138. https:\/\/doi.org\/10.1007\/s00464-018-6541-1.","journal-title":"Surg Endosc"},{"key":"1461_CR31","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s12325-018-0824-8","volume":"36","author":"CM Apovian","year":"2019","unstructured":"Apovian CM, Okemah J, O\u2019Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36:44\u201358. https:\/\/doi.org\/10.1007\/s12325-018-0824-8.","journal-title":"Adv Ther"},{"key":"1461_CR32","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1016\/S0140-6736(08)60762-X","volume":"371","author":"J Weng","year":"2008","unstructured":"Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, et al. Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. Lancet. 2008;371:1753\u201360. https:\/\/doi.org\/10.1016\/S0140-6736(08)60762-X.","journal-title":"Lancet"},{"key":"1461_CR33","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S0140-6736(15)00075-6","volume":"386","author":"G Mingrone","year":"2015","unstructured":"Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Nanni G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964\u201373. https:\/\/doi.org\/10.1016\/S0140-6736(15)00075-6.","journal-title":"Lancet"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01461-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-023-01461-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-023-01461-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T15:16:13Z","timestamp":1700579773000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-023-01461-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1461"],"URL":"https:\/\/doi.org\/10.1186\/s12902-023-01461-9","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"11 February 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study has been approved by the Medical Ethics Committee of the Jiangsu Hospital of Integrated Traditional Chinese and Western Medicine (2021-LWKYZ-002) according to the Medical Research Involving Human Subjects Act and the standards of Good Clinical Practice. Written informed consent will be obtained from all participants prior to study participation.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"215"}}